Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00010192 · ClinicalTrials.gov registry record · Phase 1
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00010192: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00010192 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00010192, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining rituximab with interleukin-2 may kill more cancer cells. Phase I trial to study the effectiveness of rituximab plus interleukin-2 in treating patients who have hematologic cancer.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL rituximab
- OTHER pharmacological study
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2000-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00010192
The ClinicalTrials.gov registry entry for NCT00010192 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00010192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00010192 about?
NCT00010192 is a clinical study titled "Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer". Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining rituximab with interleukin-2 may kill more cancer c...
What is the current status of trial NCT00010192?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2000-12.
What interventions are being tested in trial NCT00010192?
The interventions under investigation include: laboratory biomarker analysis (OTHER), rituximab (BIOLOGICAL), pharmacological study (OTHER), aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00010192?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.